Lindsey Aurora
Cardiovascular Disease · Detroit, MINPI 1003200056
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (48.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 86.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $8,514 and has fallen 94.4% since, to $475 in 2025.
Across 70 payments — averaging $187.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Abiomed$765
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$167
- Livanova USA, Inc.$133
- AstraZeneca$125
- Amgen$104
- plus $512 from 9 others
Across 7 payments — averaging $3578.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$25K
What the payments were for
- Grants$6,36448%
- Travel & lodging$2,46619%
- Food & beverage$3,63828%
- Education$6805%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 46 | $11,340 |
| Abiomed | 8 | $765 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $167 |
| Livanova USA, Inc. | 1 | $133 |
| AstraZeneca | 1 | $125 |
| Amgen | 1 | $104 |
| Bard Peripheral Vascular, Inc. | 1 | $104 |
| Cardiovascular Systems Inc. | 1 | $96 |
| Procyrion, Inc. | 1 | $81 |
| Bayer | 1 | $81 |
| Teleflex LLC | 1 | $66 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Edwards Lifesciences | 1 | $23 |
| Novo Nordisk | 1 | $18 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,148 in reported general payments places this provider in the 80th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 57 | $57,447 |
| Sirolimus | 17 | $7,515 |
| Tacrolimus | 25 | $6,158 |
| Bumetanide | 15 | $1,258 |
| Amiodarone Hcl | 12 | $641 |
| Isosorbide Dinitrate | 14 | $632 |
| Mycophenolate Mofetil | 18 | $583 |
| Hydralazine Hcl | 33 | $581 |
| Spironolactone | 48 | $482 |
| Losartan Potassium | 56 | $464 |
| Atorvastatin Calcium | 26 | $388 |
| Nifedipine ErNifedipine | 11 | $372 |
| Potassium Chloride | 18 | $328 |
| Metoprolol Succinate | 19 | $290 |
| Ezetimibe | 13 | $187 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Detroit
- Pedro Villablanca SpinettoDetroit$620K
- Wayne WeaverDetroit$340K
- Brian OneillDetroit$250K
- Karthikeyan AnanthasubramaniamDetroit$112K
- Gerald KoenigDetroit$96K
- David LanfearDetroit$82K
- Celeste WilliamsDetroit$70K
- Mahir ElderDetroit$68K
- Cori RussellDetroit$67K
- Pedro Engel GonzalezDetroit$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.